Annual Review | Professor Hui Wei: Progress in Clinical Diagnosis and Treatment of Acute Myeloid Leukemia (AML)

Annual Review | Professor Hui Wei: Progress in Clinical Diagnosis and Treatment of Acute Myeloid Leukemia (AML)

2024.03.07
With ardent vigor and unwavering dedication, the past year has seen significant advances in the field of hematologic oncology, driven by the rapid development of innovative therapies and cutting-edge technologies. The application of novel molecular biology techniques has not only refined the prognostic stratification of Acute Myeloid Leukemia (AML) but has also fostered more precise diagnostics and treatments. At the turn of the year, Oncology Frontier - Hematology Frontier has invited Professor Hui Wei, Director of the Leukemia Diagnosis and Treatment Center at the Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, to review the latest advancements in the precise diagnosis and treatment of AML in 2023, and to look forward to the future prospects and directions of AML treatment.
Professor LanPing Xu: Hematopoietic Stem Cell Transplantation for the Treatment of Severe Aplastic Anemia | 2024 CSCO Hematology Academic Conference

Professor LanPing Xu: Hematopoietic Stem Cell Transplantation for the Treatment of Severe Aplastic Anemia | 2024 CSCO Hematology Academic Conference

2024.03.07
From January 26 to 28, 2024, the "Chinese Society of Clinical Oncology (CSCO) Leukemia Committee, Lymphoma Committee, and Myeloma Preparatory Committee Work Meeting and 2024 CSCO Blood, Lymphoma, and Myeloma Diseases Academic Conference" was held in Haikou. Many authoritative hematologists from home and abroad gathered to share their insights. Professor LanPing Xu from the Hematology Institute of Peking University People's Hospital delivered an in-depth lecture on the topic of "Hematopoietic Stem Cell Transplantation for the Treatment of Severe Aplastic Anemia (SAA)," providing rich and fascinating content, summarized by "Oncology Outlook-Blood News."
Professor Huilai Zhang : Diligently Striving to Improve Survival Time and Quality of Life for Lymphoma Patients in China | 2024 CSCO Hematology

Professor Huilai Zhang : Diligently Striving to Improve Survival Time and Quality of Life for Lymphoma Patients in China | 2024 CSCO Hematology

2024.03.06
Lymphoma is one of the fastest-growing malignant tumors worldwide, and the incidence rate in China has been gradually increasing in recent years, posing a serious threat to the health of the population. From January 26 to 28, 2024, the "Work Conference of the Leukemia Committee, Lymphoma Committee, and Myeloma Preparatory Committee of the Chinese Society of Clinical Oncology (CSCO) and the 2024 CSCO Academic Conference on Hematology, Lymphoma, and Myeloma Diseases" was successfully held in Haikou. Professor Huilai Zhang from Tianjin Medical University Cancer Institute and Hospital shared insights at the conference on the survival status and diagnosis and treatment strategies for patients with indolent lymphoma, frontline treatment strategies for mantle cell lymphoma, and research progress on immunosuppressants. Following the conference, Oncology Frontier - Hematology Frontier invited Professor Zhang for an in-depth sharing session.
Professor Shuye Wang: Emphasizing early diagnosis and treatment of systemic amyloidosis to improve patient cure rates | 2024 CSCO Hematology Academic

Professor Shuye Wang: Emphasizing early diagnosis and treatment of systemic amyloidosis to improve patient cure rates | 2024 CSCO Hematology Academic

2024.03.06
Due to its low incidence and diverse clinical manifestations, patients with AL amyloidosis are often misdiagnosed or underdiagnosed, resulting in insufficient treatment. From January 26th to 28th, 2024, the "China Society of Clinical Oncology (CSCO) Leukemia Expert Committee, Lymphoma Expert Committee, and Myeloma Preparatory Committee Working Meeting, and the 2024 CSCO Hematology, Lymphoma, and Myeloma Disease Academic Conference" was successfully held in Haikou. During the conference, Professor Shuye Wang from the First Affiliated Hospital of Harbin Medical University shared insights with Oncology Frontier - Hematology Frontier on the current status of diagnosis and treatment of systemic amyloidosis, perspectives on early diagnosis, and the future research plans of his team.
Professor Yang Liang:Research Progress and Reflections on BTK Inhibitors in the Treatment of CLL Patients | 2024 CSCO Hematology Academic Conference

Professor Yang Liang:Research Progress and Reflections on BTK Inhibitors in the Treatment of CLL Patients | 2024 CSCO Hematology Academic Conference

2024.03.06
In recent years, with the emergence of new targeted drugs such as ibrutinib and zanubrutinib, the treatment strategies for chronic lymphocytic leukemia (CLL) patients have been changing, sparking widespread discussions. At the recent 2024 CSCO Hematology Academic Conference, Professor Yang Liang from Sun Yat-sen University Cancer Center shared some thoughts on the classical international phase III clinical trial designs of BTK inhibitors and related issues. "Oncology Frontier - Hematology Frontier" specially invited Professor Yang Liang to discuss the progress in CLL treatment and the design of the ALPINE study.
Professor Kailin Xu : From Clinical to Scientific Questions—Entry Points for CAR-T Research | 2024 CSCO Hematology Conference

Professor Kailin Xu : From Clinical to Scientific Questions—Entry Points for CAR-T Research | 2024 CSCO Hematology Conference

2024.03.06
CAR-T cell therapy is currently a hot research topic in the field of hematology, but how to transform the clinical issues of CAR-T cell therapy into scientific research questions remains a challenge for many clinicians. From January 26th to 28th, 2024, the "Chinese Society of Clinical Oncology (CSCO) Leukemia Committee, Lymphoma Committee, and Myeloma Preparatory Committee Work Meeting and 2024 CSCO Hematology, Lymphoma, and Myeloma Academic Conference" was grandly held in the beautiful city of Haikou. At the conference, Professor Kailin Xu , Director of the Hematology Institute at Xuzhou Medical University, shared his experience and insights on transforming clinical issues of CAR-T cell therapy into scientific research questions from five aspects under the topic "From Clinical to Scientific Questions—Entry Points for CAR-T Clinical Research." His insights are of great reference and significance for conducting related research, and are specially compiled as follows.